Issues in the Treatment of GIST in South Korea

Yoon-Koo Kang
Asan Medical Center, University of Ulsan,
Seoul, Korea
Strength of Korea in the Treatment of GIST

• Nationwide medical insurance system
• Easy access to expert physicians and hospitals because Korea is a small country
• Strong patient advocacy group

아산 기스트 환우회
https://cafe.naver.com/koreagist
Access to new agents

• Avapritinib
  – We have participated in global clinical trials of avapritinib (phase I Navigator and phase 3 Voyager trials)
  – Now patients with D842V-mutant GISTs can be treated in EAP
  – No application to Korean FDA yet

• Ripretinib
  – We have participated in phase 3 Intrigue trial for 2nd line GISTs)
  – No EAP or application to Korean FDA yet
No reimbursement of Imatinib Resumption

- Even though benefit has been demonstrated in RIGHT study
- Because of no difference in OS: due to cross-over allowed
Mandatory CT scan every 3 months

- Mandatory CT scan at least every 3 months for TKI treatment including 1st line imatinib to be reimbursed.
- Concerns about radiation hazard and renal dysfunction (due to contrast dye) with frequent CT scan
- An issue for those with metastatic GIST who are maintained with no visible tumors for many years after imatinib treatment alone or in combination with surgical resection of residual lesions

**Overall survival according to time periods**

- Period 1 (2001-2007)
- Period 2 (2008-2014)

**Progression-free survival according to time periods**

- Period 1 (2001-2007)
- Period 2 (2008-2014)
Thank you.